Literature DB >> 34571277

Agonist antibody discovery: Experimental, computational, and rational engineering approaches.

John S Schardt1, Harkamal S Jhajj2, Ryen L O'Meara3, Timon S Lwo2, Matthew D Smith3, Peter M Tessier4.   

Abstract

Agonist antibodies that activate cellular signaling have emerged as promising therapeutics for treating myriad pathologies. Unfortunately, the discovery of rare antibodies with the desired agonist functions is a major bottleneck during drug development. Nevertheless, there has been important recent progress in discovering and optimizing agonist antibodies against a variety of therapeutic targets that are activated by diverse signaling mechanisms. Herein, we review emerging high-throughput experimental and computational methods for agonist antibody discovery as well as rational molecular engineering methods for optimizing their agonist activity.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activation; Agonist; Antibody; Biologic; Discovery; Engineering; Function-based screening; High throughput; mAb; signaling

Mesh:

Substances:

Year:  2021        PMID: 34571277      PMCID: PMC8714685          DOI: 10.1016/j.drudis.2021.09.008

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  108 in total

1.  Generation of a novel artificial TrkB agonist, BM17d99, using T7 phage-displayed random peptide libraries.

Authors:  Toshiyuki Ohnishi; Kotaro Sakamoto; Asano Asami-Odaka; Kimie Nakamura; Ayako Shimizu; Takashi Ito; Taiji Asami; Tetsuya Ohtaki; Hiroshi Inooka
Journal:  Biochem Biophys Res Commun       Date:  2016-12-31       Impact factor: 3.575

2.  Selection of single chain antibody fragments binding to the extracellular domain of 4-1BB receptor by phage display technology.

Authors:  Salman Bagheri; Mehdi Yousefi; Elmira Safaie Qamsari; Farhad Riazi-Rad; Mohsen Abolhassani; Vahid Younesi; Ruhollah Dorostkar; Ali Akbar Movassaghpour; Zahra Sharifzadeh
Journal:  Tumour Biol       Date:  2017-03

3.  Antibody selection using clonal cocultivation of Escherichia coli and eukaryotic cells in miniecosystems.

Authors:  Tianqing Zheng; Jia Xie; Zhuo Yang; Pingdong Tao; Bingbing Shi; Lacey Douthit; Peng Wu; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-18       Impact factor: 11.205

Review 4.  Therapeutic Fc-fusion proteins: Current analytical strategies.

Authors:  Bastiaan L Duivelshof; Amarande Murisier; Julien Camperi; Szabolcs Fekete; Alain Beck; Davy Guillarme; Valentina D'Atri
Journal:  J Sep Sci       Date:  2020-09-29       Impact factor: 3.645

5.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

Authors:  Chengbin Wu; Hua Ying; Christine Grinnell; Shaughn Bryant; Renee Miller; Anca Clabbers; Sahana Bose; Donna McCarthy; Rong-Rong Zhu; Ling Santora; Rachel Davis-Taber; Yune Kunes; Emma Fung; Annette Schwartz; Paul Sakorafas; Jijie Gu; Edit Tarcsa; Anwar Murtaza; Tariq Ghayur
Journal:  Nat Biotechnol       Date:  2007-10-14       Impact factor: 54.908

Review 6.  Wound repair and regeneration: mechanisms, signaling, and translation.

Authors:  Sabine A Eming; Paul Martin; Marjana Tomic-Canic
Journal:  Sci Transl Med       Date:  2014-12-03       Impact factor: 17.956

7.  Functional screening system for yeast-secreted peptides acting on G-protein coupled receptors.

Authors:  Tomohiro Shigemori; Kouichi Kuroda; Mitsuyoshi Ueda
Journal:  AMB Express       Date:  2015-05-13       Impact factor: 3.298

Review 8.  Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms.

Authors:  Kashyap R Patel; Jacob T Roberts; Adam W Barb
Journal:  Front Immunol       Date:  2019-02-14       Impact factor: 7.561

Review 9.  Cytokines in clinical cancer immunotherapy.

Authors:  Pedro Berraondo; Miguel F Sanmamed; María C Ochoa; Iñaki Etxeberria; Maria A Aznar; José Luis Pérez-Gracia; María E Rodríguez-Ruiz; Mariano Ponz-Sarvise; Eduardo Castañón; Ignacio Melero
Journal:  Br J Cancer       Date:  2018-11-09       Impact factor: 7.640

10.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Authors:  Yiska Weisblum; Fabian Schmidt; Fengwen Zhang; Justin DaSilva; Daniel Poston; Julio Cc Lorenzi; Frauke Muecksch; Magdalena Rutkowska; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Christian Gaebler; Marianna Agudelo; Alice Cho; Zijun Wang; Anna Gazumyan; Melissa Cipolla; Larry Luchsinger; Christopher D Hillyer; Marina Caskey; Davide F Robbiani; Charles M Rice; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz
Journal:  Elife       Date:  2020-10-28       Impact factor: 8.140

View more
  1 in total

1.  Joined at the hip: The role of light chain complementarity determining region 2 in antibody self-association.

Authors:  Paul R Sargunas; Jamie B Spangler
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-01       Impact factor: 12.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.